Issue Stories
Q3 Sleep Center Survey
Home testing shakes the market, but worry is waning.
This year, Sleep Review partnered with Wachovia Capital
Markets LLC to conduct our annual salary survey and Q3
market survey of sleep centers. Survey data was compiled
from responses that were
received from 772 sleep
laboratories between June
23 and July 1, 2008.
Results of Wachovia's Q1
Sleep Center Survey
indicated that
sleep labs were limiting their expansion plans given
Medicare's proposal to cover home testing for obstructive
sleep apnea (OSA). In fact, in the report (released February
12, 2008), 40% of the respondents indicated that home testing
had affected their expansion plans. Now, results of the Sleep
Review/Wachovia Q3 Sleep Center Survey indicate that sleep lab
expansion is expected to stabilize as concern about the impact of
home sleep testing is fading.
CONDUCTING THE SURVEY
For the first time, Sleep Review partnered with equity research firm, Wachovia Capital Markets LLC. Among the roughly
12,500 sleep professionals to whom we sent the survey, 772 responded to one or more of the survey questions for a response
rate of 6%. Because none of the questions in this survey were mandatory, the response rates varied from question to question.
We received responses from a range of sleep industry participants with registered polysomnographic technicians (37% of
respondents) and sleep center directors/supervisors/managers (29% of respondents) representing the most common titles.
Responses also covered every geographic region (and nearly every state) in the United States. |
SURVEY SAYS ... |
Sleep center expansion slowed over the past year but looks
likely to stabilize over the next year.
Bed Growth During Prior 12 Months: Respondents saw bed
growth of 13% during the past 12 months and reported an
average of 7.2 beds per respondent
versus 6.4 beds per respondent
12 months ago. We should
note that sleep center growth covers
only part of the entire sleep
market, as sleep center growth
drives new diagnoses and flow
generator sales, while mask sales
are mostly driven by replacement
sales. Moreover, sleep center
growth as defined in the survey
only represents organic growth
(beds per center) versus inorganic
growth (new sleep centers).
That being said, the survey demonstrates a decrease in bed
growth to a level in the low teens range. The sharp slowdown
in sleep laboratory expansion may have been driven by the
prospect of home sleep testing. Medicare proposed coverage of
home testing in December 2007 and then finalized coverage in
March 2008. Given the uncertain repercussions posed by the
coverage decision, it is not surprising that sleep laboratories
may have slowed expansion around this time.
The survey indicates that flow generators (driven mainly by
new patients) have been growing at 8% to 10%, while masks
(driven by both new patients and increasing replacement among
existing patients) have grown at 13% to
15%; combined, this puts the market in
the low teens.
Expected Bed Growth During Next
12 Months: Respondents expect
faster sleep center capacity expansion
in the next 12 months (17% to 8.4
beds per respondent) than the growth
seen in the past 12 months. However,
prior surveys indicate that sleep centers
tend to overestimate their projected
growth rates by 150% to
200%. Therefore, sleep center growth
is likely to be stable in the low teens
over the next 12 months.
Why the stabilization? Analysts believe that the sleep centers’
initial fears of home testing may be easing because reimbursement
is likely to be less than expected and because
CMS has restricted home medical equipment providers from
administering tests. |
PORTABLE MONITORING IN SLEEP CENTERS SLOW GOING |
|
On the home testing front, respondents indicated that home testing
would most likely get a lukewarm reception at sleep centers. Currently,
just 13% of the sleep centers offer home sleep tests. In the next 6 months,
another 33% expect to start offering home sleep tests. However, when
asked about what level of reimbursement it would take for the sleep centers
to adopt home testing, the average response was $428 per test. That
figure is far from G-code reimbursement rates released by carriers such as
HealthNow New York Inc, doing business as Blue Shield of Western New
York. Those rates are:
Code |
PAR Fee |
Non PAR Fee |
Limiting Charge |
G0398 |
$248.39 |
$235.97 |
$271.37 |
G0399 |
$191.09 |
$181.54 |
$208.77 |
G0400 |
$171.99 |
$163.39 |
$187.90 |
These payment
rates are below the
$428 rate it would
take for the average,
surveyed lab to
adopt home testing.
Consequently, adoption
of home testing
by sleep centers may be limited.
Supporting the thesis that the uncertainty created by home testing
coverage has slowed sleep laboratory expansion and growth
expectations is the fact that 23% of sleep laboratories surveyed
indicated that the potential for increased use of home diagnosis has
affected their expansion plans.
The sleep centers expect to make only moderate changes to
their practices in the face of increased use of home testing.
Approximately 38% of respondents say that they would increase
involvement with home testing, while only 2% would reduce the
number of beds at their facilities, 1% would close facilities, and
27% expect to make no changes. |
MORE PATIENT VOLUME EXPECTED |
|
Respondents reported that overall, sleep centers have seen patient volume
grow by 11% in the past 12 months and expect 13% growth in the next 12
months; the most common response for both was 10% to 14% growth..
These numbers are slightly behind both the reported and expected bed
growth rates (which were 13% and 17%, respectively). Wachovia analysts are
not sure how to explain the discrepancy between these two questions; however,
one possible explanation might be that there is a lag between sleep center
expansion and
patient volume
growth.
It is only the
third time that
our survey partner,
Wachovia,
has asked this
particular question
about future
growth, so it is a
bit early to evaluate
longer term
trends in patient
volume. Last 12
months growth in
this survey was down slightly from Wachovia's prior two surveys (10% versus
13% and 13%) though next 12 months growth in this survey was between their
prior two surveys (13% versus 17% and 10%). |
SELLING SLEEP THERAPY EQUIPMENT |
The survey shows a gradual increase in
sleep laboratories selling sleep therapy
equipment from 16% of laboratories in a
Wachovia Q1 2006 survey to 19% in the
Q3 2008 survey. Some laboratories have
started to view equipment as an additional
revenue source and a way to offset
potential losses to home sleep testing.
However, this revenue model might be
challenged (at least for Medicare patients)
given a proposal from CMS to disallow
CPAP sales by companies administering
tests and vice versa. This CMS proposal is
not final, however.
It should be noted that information
in this report has been obtained or
derived from sources believed by Sleep
Review to be reliable. Any opinions or
estimates contained in this report
represent the judgment of Sleep Review
and Wachovia Capital Markets LLC at this
time, and are subject to change
without notice. We advise readers to
compare our results to other surveys.To view the full breakdown of the number
of our regional responses, view the complete results here. |
|
|
LOOKING FOR EXPERT ADVICE?
|
 |
|
|
|